## Pathophysiology of Myasthenia Gravis ### Clinical Presentation **Key Point:** Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction, characterized by muscle weakness and fatigability that worsens with activity and improves with rest. ### Correct Statements (Options 0, 1, 3) **Option 0 — Autoimmune Mechanism:** - Autoantibodies (IgG) bind to nicotinic acetylcholine receptors - Two pathogenic mechanisms: 1. **Complement activation** → membrane attack complex formation → destruction of junctional folds 2. **Cross-linking and internalization** of receptors → increased receptor turnover and loss - Results in reduced number of functional acetylcholine receptors at the motor end plate **Option 1 — Reduced Safety Margin:** - Normal neuromuscular transmission has a large safety margin (5–10 fold) - In MG, fewer receptors and antibody-mediated damage reduce this margin - With repetitive stimulation, acetylcholine release may be insufficient to depolarize the muscle membrane - Explains the characteristic **fatigue** — weakness worsens with repeated activity **Option 3 — Anticholinesterase Therapy:** - Drugs like neostigmine and pyridostigmine inhibit acetylcholinesterase - Prolongs acetylcholine residence time in the synaptic cleft - Increases probability of acetylcholine binding to remaining functional receptors - Improves muscle strength in MG patients - **High-Yield:** This is the first-line symptomatic treatment ### Incorrect Statement (Option 2) — **THE ANSWER** **Warning:** Acetylcholine **synthesis is NOT impaired** in myasthenia gravis. - Choline acetyltransferase activity is **normal** in the presynaptic terminal - Acetylcholine production and release are **intact** - The problem is **postsynaptic** — reduced number of functional receptors to bind acetylcholine - This is why increasing acetylcholine levels (via anticholinesterases) helps, but does not cure the disease - ~~Presynaptic defects~~ (such as Lambert-Eaton myasthenic syndrome, which involves calcium channel antibodies) are a different disorder ### Pathophysiology Flowchart ```mermaid flowchart TD A[Autoimmune Response]:::outcome --> B[IgG Antibodies to AChR]:::outcome B --> C{Mechanism}:::decision C -->|Complement Activation| D[Membrane Attack Complex]:::action C -->|Cross-linking| E[Receptor Internalization]:::action D --> F[Junctional Fold Destruction]:::outcome E --> G[Increased Receptor Turnover]:::outcome F --> H[Reduced Functional AChRs]:::urgent G --> H H --> I[Reduced Safety Margin]:::outcome I --> J[Muscle Weakness & Fatigue]:::outcome K[Presynaptic ACh Synthesis: NORMAL]:::action -.->|Not affected| H ``` ### Comparison: MG vs. Lambert-Eaton Myasthenic Syndrome (LEMS) | Feature | Myasthenia Gravis | LEMS | | --- | --- | --- | | **Site of Defect** | Postsynaptic (AChR) | Presynaptic (Ca²⁺ channels) | | **Antibody Target** | Acetylcholine receptors | Voltage-gated calcium channels | | **Acetylcholine Release** | Normal | Reduced | | **Acetylcholine Synthesis** | Normal | Normal | | **Fatigue Pattern** | Worsens with activity | Improves with activity ("warm-up" phenomenon) | | **Anticholinesterase Response** | Beneficial | Minimal benefit | | **Association** | Thymic abnormality (70%) | Small cell lung cancer (50%) | **Clinical Pearl:** The distinction between MG (postsynaptic) and LEMS (presynaptic) is critical — LEMS patients show **improvement** with repetitive stimulation (opposite of MG), and anticholinesterases are ineffective.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.